Home
/
CRESCENT BIOPHARMA, INC.
/
Financials
/
Quarterly
CRESCENT BIOPHARMA, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that CRESCENT BIOPHARMA, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2016
$18.5K
Nov 8, 2017
Q3
2016
Sep 30, 2015
$20.04M
Nov 4, 2016
Q2
2018
Jun 30, 2015
$20.00M
Aug 9, 2018
Q3
2018
Jun 30, 2015
$20.00M
Nov 2, 2018
Q1
2015
Mar 31, 2015
$0
May 5, 2015
Q3
2015
Sep 30, 2014
$15.03M
Nov 12, 2015
Q2
2015
Jun 30, 2014
$15.03M
Aug 6, 2015
Q3
2018
May 31, 2014
$15.00M
Nov 2, 2018
Q2
2018
May 31, 2014
$15.00M
Aug 9, 2018
Q1
2015
Mar 31, 2014
$0
May 5, 2015
Q3
2014
Sep 30, 2013
$52.6K
Oct 31, 2014
Q2
2014
Jun 30, 2013
$55.1K
Jul 31, 2014
Q1
2014
Mar 31, 2013
$3.81M
May 9, 2014
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($24.61M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($21.79M)
Jul 31, 2025
Q3
2025
Jun 30, 2025
($21.79M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($2.34M)
May 14, 2025
Q3
2025
Mar 31, 2025
($15.15M)
Nov 6, 2025
Q2
2025
Mar 31, 2025
($15.15M)
Jul 31, 2025
Q3
2025
Sep 30, 2024
($2.63M)
Nov 6, 2025
Q2
2024
Jun 30, 2024
($10.10M)
Aug 8, 2024
Q3
2024
Jun 30, 2024
($10.10M)
Nov 13, 2024
Q1
2025
Mar 31, 2024
($10.74M)
May 14, 2025
Q2
2024
Mar 31, 2024
($10.74M)
Aug 8, 2024
Q3
2024
Mar 31, 2024
($10.74M)
Nov 13, 2024
Q3
2024
Sep 30, 2023
($9.20M)
Nov 13, 2024
Q3
2024
Jun 30, 2023
($8.26M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($8.26M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($10.36M)
May 9, 2024
Q2
2024
Mar 31, 2023
($10.36M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($10.36M)
Nov 13, 2024
Q3
2023
Sep 30, 2022
($8.52M)
Nov 3, 2023
Q3
2023
Jun 30, 2022
($13.27M)
Nov 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($25.89M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($21.03M)
Jul 31, 2025
Q1
2025
Mar 31, 2025
($2.40M)
May 14, 2025
Q3
2025
Sep 30, 2024
($2.63M)
Nov 6, 2025
Q2
2024
Jun 30, 2024
($10.36M)
Aug 8, 2024
Q1
2025
Mar 31, 2024
($11.12M)
May 14, 2025
Q3
2024
Sep 30, 2023
($9.81M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($8.93M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($10.94M)
May 9, 2024
Q3
2023
Sep 30, 2022
($8.77M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($13.35M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($14.66M)
May 3, 2023
Q3
2022
Sep 30, 2021
($17.34M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($14.40M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($14.28M)
Apr 28, 2022
Q3
2021
Sep 30, 2020
($13.73M)
Nov 2, 2021
Q2
2021
Jun 30, 2020
($14.11M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($8.11M)
May 3, 2021
Q3
2020
Sep 30, 2019
($14.11M)
Nov 6, 2020
Q2
2020
Jun 30, 2019
($16.82M)
Jul 31, 2020